Cancer Treatments Online | eviQ A free resource of evidence-based, consensus driven cancer treatment protocols and information for use at the point of care eviQ is developed for the Australian context and supports health professionals in the delivery of cancer treatments
4102-Breast neoadjuvant adjuvant AC (DOXOrubicin and . . . - eviQ Protocol published on eviQ Next review in 1 year As ID 4102 Breast adjuvant neoadjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) dose dense replaces two existing approved protocols, their individual History sections are included below for consistency in documentation
Protocols and documents - eviQ All eviQ treatment protocols are periodically reviewed every one, two or four years to ensure content is based on the latest rigorous evidence Protocols are stratified into three groups according the following criteria:
Medical oncology - eviQ Updated protocols The following protocols have received important updates in the past 90 days: Nasopharyngeal locally advanced ciSplatin and gemcitabine (induction) Head and neck squamous cell carcinoma locally advanced definitive cARBOplatin and fluorouracil chemoradiation
eviQ protocols eviQ will start releasing updated protocols in a sequential manner - one tumour stream at a time The first update will commence with breast protocols on the afternoon of Wednesday 19 July 2023, followed by subsequent releases as depicted in the image above
Haematology and BMT - eviQ Recently added protocols The following protocols have been added in the past 90 days: Decitabine and cedazuridine oral; Nelarabine; Non-Hodgkin lymphoma glofitamab and oBINUTUZumab; Acute myeloid leukaemia induction FLAG-Ida-Ven (fludarabine cytarabine filgrastim iDArubicin and venetoclax)
4115-Breast neoadjuvant adjuvant trastuzumab three weekly - eviQ Protocol published on eviQ Next review in 2 years As ID 4115 Breast adjuvant neoadjuvant trastuzumab three weekly replaces two existing approved protocols, their individual History sections are included below for consistency in documentation